Extracellular HMGB1 as a therapeutic target in inflammatory diseases

U Andersson, H Yang, H Harris - Expert opinion on therapeutic …, 2018 - Taylor & Francis
U Andersson, H Yang, H Harris
Expert opinion on therapeutic targets, 2018Taylor & Francis
Introduction: High-mobility group box 1 (HMGB1) is a ubiquitous nuclear protein that
promotes inflammation when released extracellularly after cellular activation, stress,
damage or death. HMGB1 operates as one of the most intriguing molecules in inflammatory
disorders via recently elucidated signal and molecular transport mechanisms. Treatments
based on antagonists specifically targeting extracellular HMGB1 have generated
encouraging results in a wide number of experimental models of infectious and sterile …
Abstract
Introduction: High-mobility group box 1 (HMGB1) is a ubiquitous nuclear protein that promotes inflammation when released extracellularly after cellular activation, stress, damage or death. HMGB1 operates as one of the most intriguing molecules in inflammatory disorders via recently elucidated signal and molecular transport mechanisms. Treatments based on antagonists specifically targeting extracellular HMGB1 have generated encouraging results in a wide number of experimental models of infectious and sterile inflammation. Clinical studies are still to come.
Areas covered: We here summarize recent advances regarding pathways for extracellular HMGB1 release, receptor usage, and functional consequences of post-translational modifications. The review also addresses results of preclinical HMGB1-targeted therapy studies in multiple inflammatory conditions and outlines the current status of emerging clinical HMGB1-specific antagonists.
Expert opinion: Blocking excessive amounts of extracellular HMGB1, particularly the disulfide isoform, offers an attractive clinical opportunity to ameliorate systemic inflammatory diseases. Therapeutic interventions to regulate intracellular HMGB1 biology must still await a deeper understanding of intracellular HMGB1 functions. Future work is needed to create more robust assays to evaluate functional bioactivity of HMGB1 antagonists. Forthcoming clinical studies would also greatly benefit from a development of antibody-based assays to quantify HMGB1 redox isoforms, presently assessed by mass spectrometry methods.
Taylor & Francis Online